Hemispherx Biopharma Announces Retention of New Senior Personnel and Contractors Ahead of Key NDA Filing for Chronic (Business Wire via Yahoo! Finance)
PHILADELPHIA----April 25, 2006--Hemispherx Biopharma, Inc. today announced that it has retained a team of scientists and executives with unique experience in immunology, pharma manufacturing, and regulatory compliance to help the Company prepare for the filing of a new drug application for the experimental immunostimulant Ampligen , developed for the potential treatment of Chronic Fatigue